FindMyKOL
Clinical trialNCT00984217WithdrawnPhase 2Interventional

Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies

NCT00984217 is a phase 2 interventional trial sponsored by University of Pittsburgh. As of 21 Nov 2026, it was withdrawn. It studies Panitumumab in Adenoma, Pleomorphic, Mixed Salivary Gland Tumor and 2 more conditions. The registry lists an enrollment of 0 participants at 27 sites in 1 country. The registry lists a start date of 31 Aug 2011 and a primary completion date of 31 Aug 2011.

SponsorUniversity of Pittsburgh →Enrollment0Adenoma, PleomorphicMixed Salivary Gland TumorSalivary Gland Tumor, MixedSyringoma, Chondroid
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00984217
FieldValue
Registry IDNCT00984217
StatusWithdrawn
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of Pittsburgh
Enrollment0
Registered sites27
Countries1
ConditionsAdenoma, Pleomorphic, Mixed Salivary Gland Tumor, Salivary Gland Tumor, Mixed and Syringoma, Chondroid
DrugsPanitumumab
Start31 Aug 2011
Primary completion31 Aug 2011
Study completion31 Aug 2011
Last update posted8 Jan 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Standard therapy for high-risk or locally advanced salivary gland malignancies is surgery followed by postoperative radiation therapy. Retrospective studies have shown the superiority of combined modality therapy compared to surgery alone for patients with advanced T or N stage. Despite the addition of postoperative radiation therapy, the five-year survival for locally advanced salivary gland malignancies is poor (less than 60%). In salivary gland malignancies, the epidermal growth factor receptor (EGFR) is expressed in 25-85%; in certain histological types, like salivary duct carcinomas, the expression is higher. EGFR is a promising target of anticancer therapy. In squamous cell carcinoma of the head and neck, a phase III trial utilizing cetuximab added to radiation therapy improved both locoregional control and overall survival compared to radiation alone. Panitumumab is a novel, human, IgG2 EGFR monoclonal antibody that may be better tolerated and more efficacious than cetuximab. Here, the investigators suggest that the addition of panitumumab to standard radiotherapy in locally-advanced salivary gland malignancies will improve recurrence-free survival (RFS).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Ohio, United States1 site
  • Upmc Cancer Center - Teramana Cancer Center - Steubenville

    Steubenville

Pennsylvania, United States26 sites
  • Upmc Cancer Center - Beaver

    Beaver

  • Upmc Cancer Center - Clairton

    Clairton

  • Upmc Cancer Center - Arnold Palmer Pavilion - Greensburg

    Greensburg

  • Upmc Cancer Center - Oakbrook Commons

    Greensburg

  • Upmc Cancer Center - Oakbrook Commons - Greensburg

    Greensburg

  • Upmc Cancer Center -Arnold Palmer Pavilion

    Greensburg

  • Upmc Cancer Center - Indiana

    Indiana

  • Upmc Cancer Center - John P. Murtha Pavilion - Johnstown

    Johnstown

  • Upmc Cancer Center - Mckeesport

    McKeesport

  • Upmc Cancer Center - Monroeville

    Monroeville

  • Upmc Cancer Center - Sewickley Medical Oncology/hematology Group

    Moon Township

  • Upmc Cancer Center -Mt. Pleasant

    Mount Pleasant

  • Upmc Cancer Center - New Castle

    New Castle

  • Hillman Cancer Center: University of Pittsburgh Cancer Institute / Upmc Department of Radiology

    Pittsburgh

  • Upmc Cancer Center - Passavant

    Pittsburgh

  • Upmc Cancer Center - St. Margaret's

    Pittsburgh

  • Upmc Cancer Center - Upper St. Clair

    Pittsburgh

  • Upmc Cancer Center -Delafield Rd.

    Pittsburgh

  • Upmc Cancer Center -Drake

    Pittsburgh

  • Upmc Cancer Center -Upmc Shadyside

    Pittsburgh

  • Upmc Cancer Centers

    Pittsburgh

  • Upmc Presbyterian -Radiation Oncology

    Pittsburgh

  • Upmc Cancer Center -Upmc Northwest

    Seneca

  • Upmc Cancer Center - Uniontown

    Uniontown

  • Upmc Cancer Center - Washington

    Washington

  • Upmc Cancer Center - North Hills

    Wexford

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 1 siteOH1Pennsylvania: 26 sitesPA26New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00984217

Each answer restates registry values shown on this page.

What is NCT00984217?

NCT00984217 is a phase 2 interventional trial sponsored by University of Pittsburgh. It studies Panitumumab in Adenoma, Pleomorphic, Mixed Salivary Gland Tumor and 2 more conditions.

Who leads NCT00984217?

The registry names Michael K. Gibson, MD (principal investigator, University of Pittsburgh) as the overall official.

Where does NCT00984217 run?

The registry lists 27 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00984217 study?

The registered drug and biological interventions are Panitumumab.

When did NCT00984217 end?

The registry lists a primary completion date of 31 Aug 2011 and a study completion date of 31 Aug 2011. The sponsor last updated the record on 8 Jan 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.